Influvac Junior

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

Influenza virus haemagglutinin

Disponible desde:

Abbott Australasia Pty Ltd

clase:

Medicine Registered

Información para el usuario

INFLUVAC
®
 JUNIOR

CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS
LEAFLET
This leaflet answers some of the
common questions about Influvac
Junior vaccine. It does not contain all
the available information. It does not
take the place of talking to your
doctor or pharmacist. Please read it
carefully and keep it for future
reference.
All medicines and vaccines have
risks and benefits. Your doctor has
weighed the possible risks of your
child having Influvac Junior against
the expected benefits.
TALK TO YOUR DOCTOR, NURSE OR
PHARMACIST IF YOU HAVE ANY
CONCERNS ABOUT RECEIVING INFLUVAC
JUNIOR.
Your doctor and pharmacist have
more information.
WHAT INFLUVAC
JUNIOR IS USED FOR
Influvac Junior is used to prevent
certain types of influenza (commonly
called flu). The vaccine works by
causing the body to produce its own
protection (antibodies) against three
different types of influenza virus.
Each year new types of influenza
virus can appear, so every year
Influvac Junior is changed to contain
fragments of the new types of virus.
Therefore, influenza vaccination is
recommended every year.
PLEASE NOTE THAT INFLUVAC JUNIOR
WILL ONLY PROTECT YOUR CHILD AGAINST
THE THREE TYPES OF INFLUENZA VIRUS
USED TO MAKE THE VACCINE. IT WILL
NOT PROTECT YOUR CHILD FROM
INFLUENZA CAUSED BY OTHER TYPES OF
INFLUENZA VIRUS OR FROM INFECTIONS
WITH OTHER AGENTS CAUSING FLU-LIKE
SYMPTOMS (SUCH AS THE COMMON
COLD).
Influenza is an infectious illness.
Influenza is spread by small droplets
from the nose, throat or mouth of an
infected person. Symptoms of
influenza begin 48 hours after
coming into contact with the virus.
These consist of chills, fever,
generalised aches and pains,
headache and respiratory symptoms
(sore throat, runny nose, cough). The
severity and type of symptoms can
vary. Most people recover
completely within a week. The risk
of serious complications (e.g.,
pneumonia and death) is greater in
very young, very old and chronically
ill persons.
Influvac Junior is used in children
aged 6 months to 35 months.
ANNUAL VACCIN

Ficha técnica

_Influvac Junior PI _
_Version 3 _
_Page 1 of 4 _

PRODUCT INFORMATION 

INFLUVAC

 JUNIOR 
NAME OF THE MEDICINE 
Influvac
®
 Junior Inactivated influenza vaccine (surface antigen) 
DESCRIPTION 
Influvac Junior is a clear colourless
suspension for injection. It is an egg-grown, inactivated
influenza 
virus vaccine based on isolated surface antigens of
A and B strains of myxovirus influenza.   
The type and amount of viral antigens
in Influvac Junior conform to the requirements of the Australian 
Influenza Vaccine Committee (AIVC) and the New Zealand
Ministry of Health for the winter of 2013.  
The strains chosen for vaccine manufacture are endorsed by the
AIVC as being antigenically equivalent 
to the reference virus.  
This is a purified, inactivated influenza vaccine
(surface antigen), each 0.25 mL of which contains 
antigens representative of the following type: 
A/California/7/2009 (H
1
N
1
)-like strain (A/California/7/2009 NYMC X-181) 15
µg haemagglutinin/dose 
A/Victoria/361/2009 (H
3
N
2
)-like strain (A/Victoria/361/2011 IVR-165) 15 µg haemagglutinin/dose 
B/Wisconsin/1/2010-like strain (B/Hubei-Wujiagang/158/2009
NYMC BX-39) 15 µg 
haemagglutinin/dose 
INACTIVE: 
Each 0.25 mL dose also contains potassium chloride,
potassium dihydrogen phosphate, sodium 
phosphate-dibasic dihydrate, sodium chloride, calcium chloride,
magnesium chloride and water for 
injections. 
PHARMACOLOGY 
The vaccine stimulates production of antibodies with a
specific capacity against influenza.  Protection is 
only against those strains of the virus from which the vaccine is
prepared or closely related strains. 
Seroprotection is generally obtained within 2 to 3 weeks.
 The duration of post-vaccination immunity to 
homologous strains or to strains closely related to the vaccine
strains varies, but is usually  6 to 12 
months. 
INDICATIONS 
For the prevention of influenza c